100-Year-Old Vaccine Could Offer Protection Against Covid techshout.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techshout.com Daily Mail and Mail on Sunday newspapers.
TechShout - Jul 12, 2021
A new study of antibodies produced in saliva after Pfizer-BioNTech Covid-19 vaccine shows both importance of second vaccine dose and updating vaccines to combat new variants of concern.
The study showed that the number of antibodies produced and protection offered by vaccination increased substantially after the second vaccine dose was given, showing the importance of receiving the second dose.
The team, including Nicole Schneiderhan-Marra at the University of Tubingen, also examined whether it offered protection against Alpha and Beta variants.
They found that while there was no reduction in neutralising antibodies against the Alpha variant, there was a substantial reduction in neutralising antibodies against the Beta variant, indicated the study, presented at the European Congress of Clinical Microbiology & Infectious Diseases.
Twitter Forced To Remove Tweets Criticizing Indian Govt For Poor Covid Management techshout.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techshout.com Daily Mail and Mail on Sunday newspapers.
Researchers Develop Cheaper Covid Vaccine That May Protect Against Future Strains Too - Apr 20, 2021
US researchers have developed a novel, low-cost DNA-based vaccine that may not only provide protection against existing variants of coronavirus, but also against its future strains.
The vaccine, which will cost about $1 a dose, has shown promising results in early animal testing, said the team from University of Virginia and Virginia Polytechnic Institute and State University.
“Our new platform offers a new route to rapidly produce vaccines at very low cost that can be manufactured in existing facilities around the world, which should be particularly helpful for pandemic response,” said Steven L. Zeichner from the UVA Health. The study is detailed in the journal PNAS.
Moderna Already Begins Testing Brand New Covid-19 Vaccine - Mar 16, 2021
Biotechnology company Moderna announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the company’s next generation Covid-19 vaccine candidate.
This Phase 1 dose-ranging study will assess the safety and immunogenicity of mRNA-1283, the company said in a statement.
“We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283,” said Stephane Bancel, Chief Executive Officer of Moderna.
“Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries,” Bancel added.